title: Autologous peripheral blood stem cell transplantation with induction of autologous graft-versus-host disease in acute myeloid leukemia.
abstract: We studied whether the induction of autologous graft-versus-host disease (GVHD) has an antileukemic effect and consequently increases the survival of patients undergoing autologous peripheral blood stem cell transplantation (PBSCT). In all, 22 acute myeloid leukemia patients with favorable and intermediate cytogenetic risk, in their first complete remission, were administered cyclosporine c.i.v. from day 0 to day +28 at a dose of 3.0 mg/kg per day and interferon-gamma (IFN-gamma) at 0.025 mg/m(2) s.c. every other day from day +14 to day +42 following autologous PBSCT. Natural-killer (NK)-cell activity assays and skin biopsies were performed. Successful engraftment was achieved in all patients at a median of 13 days without significant additional toxicity. Histologically confirmed cutaneous GVHD developed in 12 patients, and NK-cell activity was significantly augmented after autologous PBSCT in those patients (P=0.03). After a median follow-up duration of 37.7 months (range, 7.3-72.8), the 3-year disease-free survival (DFS) and overall survival (OS) rates were 64.4 and 73.1%, respectively, without significant correlation with GVHD status or augmentation of NK-cell activity. These data suggest that the administration of cyclosporine and IFN-gamma following autologous PBSCT improves OS and DFS, which may be attributable to the antileukemic effect, although no difference in survival could be demonstrated between cutaneous GVHD-positive and -negative groups.
authors.affiliation: Division of Hematology/Oncology, Department of Medicine, Seoul, Korea.
authors.forename: J
authors.initials: J
authors.lastname: Park
authors.forename: M H
authors.initials: MH
authors.lastname: Lee
authors.forename: H R
authors.initials: HR
authors.lastname: Lee
authors.forename: S H
authors.initials: SH
authors.lastname: Park
authors.forename: S-H
authors.initials: SH
authors.lastname: Lee
authors.forename: K-E
authors.initials: KE
authors.lastname: Lee
authors.forename: H
authors.initials: H
authors.lastname: Lee
authors.forename: J O
authors.initials: JO
authors.lastname: Park
authors.forename: K
authors.initials: K
authors.lastname: Kim
authors.forename: C W
authors.initials: CW
authors.lastname: Jung
authors.forename: Y-H
authors.initials: YH
authors.lastname: Im
authors.forename: W K
authors.initials: WK
authors.lastname: Kang
authors.forename: Y-H
authors.initials: YH
authors.lastname: Ko
authors.forename: K
authors.initials: K
authors.lastname: Park
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D016572:Cyclosporine / Q000008:administration & dosage / Q000633:toxicity; D005260:Female; D006085:Graft Survival; D006086:Graft vs Host Disease / Q000139:chemically induced / Q000276:immunology* / Q000401:mortality; D020544:Graft vs Leukemia Effect / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D007371:Interferon-gamma / Q000008:administration & dosage / Q000633:toxicity; D007694:Killer Cells, Natural / Q000276:immunology; D007951:Leukemia, Myeloid / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods* / Q000401:mortality; D010865:Pilot Projects; D016019:Survival Analysis; D014182:Transplantation, Autologous / Q000276:immunology
chemical_list: D007371:Interferon-gamma; D016572:Cyclosporine